A method and kit for specifically detecting multiple tricyclic antidepressants and its application
Through liquid chromatography tandem mass spectrometry method and optimized extract solution formula, the cross-reaction and complex pretreatment problems in the detection of tricyclic antidepressants were solved, and the rapid and accurate detection of 12 drugs was achieved, which improved the detection efficiency and Accuracy, suitable for large batches of samples.
Patent Information
- Application Number
- CN202410576898.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-05-10
AI Technical Summary
The prior art has cross-reaction, insufficient selectivity and complex pretreatment processes in the quantitative detection of tricyclic antidepressants, resulting in inaccuracy and efficiency of detection, especially for the detection of multiple antipsychotics, which is difficult for laboratories to provide. Targeted solutions, and the reagent waste and accuracy deviation are large.
The liquid chromatography tandem mass spectrometry method was adopted to extract the sample without nitrogen blowing concentration or SPE purification in one step, and the sample was treated with a mixed extract of methanol and acetonitrile. By optimizing the mass spectrometry parameters and H-ESI ionization method, the 12 types of three were achieved. High sensitivity, accuracy and specific detection of cyclic antidepressants.
It realizes rapid and accurate detection of tricyclic antidepressants in human plasma, reduces detection time and reagent cost, improves the precision and specificity of the detection, is suitable for large-scale sample detection, and extends the service life of the chromatographic column. .
Smart Images

Figure CN118465117B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of drug detection, and in particular relates to a method for specifically detecting a plurality of tricyclic antidepressants, a kit and an application thereof. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
[0003] Tricyclic antidepressants (TCAs) are a class of basic compounds that typically have a three-ring structure, including two benzene rings. TCAs were first developed in the early 1950s for the treatment of psychiatric disorders, with chlorpromazine being the first compound found to have psychiatric effects. Imipramine, a dibenzazepine analog of chlorpromazine, was the first TCA compound used to treat depression. However, the use of imipramine in some patients can induce mania with disastrous consequences. By the 1960s, some new TCAs with fewer side effects were synthesized and tested for the treatment of human mood disorders such as major depressive disorder (MMD) and other diseases such as anxiety, eating disorders, panic disorder, chronic headaches, and headaches.
[0004] Although TCAs are gradually being replaced by selective serotonin reuptake inhibitors (SSRIs) with fewer side effects, TCAs are still widely used in some regions such as North America. TCAs not only have many side effects such as dry mouth, blurred vision, constipation, hypertension, coma, respiratory depression, arrhythmia, urinary retention, cognitive and memory disorders, fever, tachycardia, etc., but also have a relatively narrow therapeutic index. Excessive use of TCAs can lead to serious toxic reactions such as cardiovascular, respiratory, and central nervous system toxicity. Therefore, for effective treatment of patients, antidepressant treatment testing is urgently needed.
[0005] Several technology platforms are commonly used in clinical chemistry laboratories for the quantitative detection of tricyclic antidepressants in human biological fluids. Immunoassays are probably the most convenient of these methods. However, many drugs with chemical structures similar to tricyclic antidepressants may cross-react with the antibody reagents of immunoassays when used in combination with TCAs, resulting in false positive results. For these reasons, immunoassays cannot currently be reliably used for the quantitative analysis of TCAs. LC-UV and GC-MS are the main analytical methods for the quantitative detection of tricyclic antidepressants in human samples such as serum, plasma, urine, and tissues. Since the UV detector is a universal detector, any compound that absorbs at the detection wavelength and co-elutes with TCAs may interfere with the accurate quantification of TCAs. LC-UV methods often lack selectivity due to the presence of many endogenous compounds in complex samples. For GC-MS, TCAs usually require derivatization to increase the volatility of the compounds, which is generally time-consuming and labor-intensive. LC-MS / MS technology, with its chromatographic separation characteristics and the advantages of high selectivity and high sensitivity of mass spectrometry, has been widely accepted by clinical chemistry laboratories for the quantitative analysis of TCAs in biological samples.
[0006] However, the inventors have found that the existing LC-MS / MS method is unable to provide targeted detection solutions for a variety of antipsychotic drugs, which are numerous and complex. It also causes waste of reagents to a certain extent. In addition, due to the large number of analyzed compounds, there are multiple compounds co-eluting in the chromatographic separation, and the selection of mass spectrometry parameters has not been optimized to the best, resulting in a certain accuracy deviation. Summary of the invention
[0007] In view of the deficiencies of the prior art, the present invention provides a method, a kit and its application for specifically detecting a variety of tricyclic antidepressants. Specifically, the present invention is based on a liquid chromatography tandem mass spectrometry method to extract 12 tricyclic antidepressants such as amitriptyline in human plasma in one step, without nitrogen concentration or SPE purification, and simultaneously detect the content of the above 12 TCAs in human plasma in a short time. Based on the above research results, the present invention is completed.
[0008] In order to achieve the above technical objectives, the technical solution adopted by the present invention is as follows:
[0009] The first aspect of the present invention provides a method for specifically detecting a plurality of tricyclic antidepressants, wherein the tricyclic antidepressants include amitriptyline, nortriptyline, maprotiline, doxepin, nordoxepin, imipramine, desipramine, trimipramine, N-desmethyltrimipramine, clomipramine, N-desmethylclomipramine, and doxepin, and the method comprises: detecting a sample to be tested after pretreatment based on LC-MS / MS;
[0010] The pretreatment method comprises adding an extracting solution to the sample to be tested, wherein the extracting solution is a mixture of methanol and acetonitrile, and the ratio of the mixed extracting solution is methanol:acetonitrile 3:1-1:2.
[0011] In a second aspect of the present invention, a kit for specifically detecting a plurality of tricyclic antidepressants is provided, wherein the kit may include: a calibrator, a calibrator diluent, a quality control product, an internal standard, an extract, an injection plate and a chromatographic column.
[0012] The third aspect of the present invention provides the use of the above method and / or kit in any one or more of the following:
[0013] a) Pharmacokinetic studies of tricyclic antidepressants;
[0014] b) Detection and evaluation of the efficacy of tricyclic antidepressants.
[0015] Compared with the prior art, the above one or more technical solutions have the following beneficial technical effects:
[0016] (1) The improvement of the pretreatment method does not require complex pretreatment processes such as SPE. Only one-step extraction and optimized extract formula are needed to detect 12 target compounds such as amitriptyline, which can meet the requirements of response value change, peak shape, carryover contamination, etc. The experimental results show that this method has high sensitivity, short analysis time, good precision, and is suitable for large-scale sample detection.
[0017] (2) The detection of amitriptyline and other compounds are all TCAs. The target compounds detected include both first-generation TCAs and new-generation TCAs. For the isomers of amitriptyline and maprotiline, the separation of isomers was achieved by optimizing and selecting mass spectrometry parameters without chromatographic separation, which saved detection time and improved detection accuracy.
[0018] (3) The sensitivity of the method detection was improved by optimizing the mass spectrometry conditions using the H-ESI ionization method; the accuracy, precision, and spike recovery rate of the methodological investigation all met the requirements of quantitative analysis; the present invention has the advantages of high accuracy, good specificity, and stable reproducibility, and can be used for the detection of TCAs compounds in human plasma.
[0019] (4) The chromatographic method was improved by using extremely low salt concentrations (0.1-2 mmol / L ammonium acetate) and formic acid concentrations (0.001-0.01%), which did not cause carryover contamination from high-concentration TCAs. The lower salt concentration and the addition of 5%-25% methanol in the aqueous phase extended the shelf life of the mobile phase. In addition, the use of low salt concentrations greatly extended the service life of the chromatographic column compared to the use of high salt concentrations, and the column efficiency decreased more slowly.
[0020] In conclusion, the above detection method and supporting kit can be applied to the therapeutic detection of TCAs drugs, which helps to provide the true level of the true concentration of the above TCAs in the subject, and therefore has good practical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.
[0022] Figure 1 It is the amitriptyline chromatogram of the present invention and its corresponding standard curve.
[0023] Figure 2 The chromatogram of nortriptyline of the present invention and its corresponding standard curve.
[0024] Figure 3 It is the maprotiline chromatogram of the present invention and its corresponding standard curve.
[0025] Figure 4 The doxepin chromatogram of the present invention and its corresponding standard curve.
[0026] Figure 5 The chromatogram of nordoxepin of the present invention and its corresponding standard curve are shown.
[0027] Figure 6 The figure is the chromatogram of imipramine of the present invention and its corresponding standard curve.
[0028] Figure 7 The chromatogram of desipramine of the present invention and its corresponding standard curve are shown.
[0029] Figure 8 It is the trimipramine chromatogram of the present invention and its corresponding standard curve.
[0030] Fig. 9 The chromatogram of N-desmethyltrimipramine of the present invention and its corresponding standard curve are shown.
[0031] Fig.10 It is the clomipramine chromatogram of the present invention and its corresponding standard curve.
[0032] Fig.11 The chromatogram of N-desmethylclomipramine of the present invention and its corresponding standard curve are shown.
[0033] Fig.12 The doxepin chromatogram of the present invention and its corresponding standard curve.
[0034] Fig.13The figure is a chromatogram showing the separation of isomers of imipramine and desmethyltrimipramine according to the present invention.
[0035] Fig.14 This is the channel interference chromatogram of maprotiline in amitriptyline of the present invention.
[0036] Fig.15 This is a chromatographic column diagram of the channel interference of amitriptyline in maprotiline of the present invention. DETAILED DESCRIPTION
[0037] It should be noted that the following detailed descriptions are all illustrative and intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.
[0038] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, they indicate the presence of features, steps, operations, devices, components and / or combinations thereof. It should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the embodiments of the present invention are intended to describe specific embodiments, rather than to limit the scope of protection of the present invention.
[0039] As mentioned above, the existing LC-MS / MS method can quantitatively analyze a variety of antipsychotic drugs, which are numerous and complex. For laboratories with fewer projects, it is impossible to provide targeted detection solutions for compounds, and it causes a certain waste of reagents. In addition, due to the large number of analyzed compounds, there are multiple compounds co-eluting in chromatographic separation, and the selection of mass spectrometry parameters is not optimized to the best, resulting in a certain accuracy deviation.
[0040] In view of this, the present invention is improved in the following aspects:
[0041] First, there are many types of psychotropic drugs involved in laboratory testing projects, and the large number of types will inevitably sacrifice the performance of some compounds, resulting in unsatisfactory performance indicators of some compounds. The liquid chromatography-tandem mass spectrometry method (LC-MS / MS) described in the present invention includes compounds that are all TCAs compounds, and does not cover other antidepressant compounds. It has high sensitivity and strong specificity, and provides the best solution for the analysis of TCAs compounds more accurately.
[0042] Second, since TCAs are alkaline compounds, they are usually present in biological samples in a protonated form at normal physiological pH. The recovery rate of TCAs can be improved by increasing the proportion of the organic phase. Most methods use a high pH buffer or sodium hydroxide solution to deprotonate TCAs compounds in biological samples before LLE. This pretreatment method requires extraction first, followed by nitrogen blowing concentration or back extraction, and the treatment process is complicated and time-consuming. The pretreatment operation of the present invention is simple and convenient. By optimizing the extract formula, high recovery extraction of the target object can be achieved in one step, without the need for nitrogen blowing concentration or SPE purification, which simplifies the sample pretreatment procedure.
[0043] Third, for the problem of high residual blood drug concentration, most methods reduce the carryover contamination rate as much as possible by increasing the acid or salt concentration in the mobile phase, but the increase in the salt concentration in the mobile phase makes it very easy for bacteria to grow in the mobile phase, shortening the shelf life of the mobile phase, and the deteriorated mobile phase is very likely to damage the internal filler of the chromatographic column, resulting in reduced column efficiency. The present invention improves the content of additives in the mobile phase, while solving the carryover contamination problem, greatly reduces reagent additives, saves reagent costs, and extends the shelf life of the mobile phase and the service life of the chromatographic column.
[0044] Fourthly, for the first-generation antidepressant amitriptyline and the second-generation antidepressant maprotiline, these two compounds are isomers and are generally not used at the same time. Therefore, most methods choose to detect only one of them, or the reagent formula includes both compounds at the same time, and the method is applied to the two compounds through chromatographic separation, which prolongs the chromatographic separation time. The present invention focuses on optimizing mass spectrometry parameters, calculates the interference rate between ion pairs under the condition of incomplete chromatographic separation, realizes the same method, is applicable to the accurate quantitative analysis of the two compounds, and the chromatographic separation time is shortened from 10-15 minutes to 6 minutes.
[0045] In view of this, in a typical embodiment of the present invention, a method for specifically detecting a plurality of tricyclic antidepressants is provided, wherein the tricyclic antidepressants include amitriptyline, nortriptyline, maprotiline, doxepin, nordoxepin, imipramine, desipramine, trimipramine, N-desmethyltrimipramine, clomipramine, N-desmethylclomipramine, and doxepin, and the method comprises: detecting the sample to be tested after pretreatment based on LC-MS / MS;
[0046] Among them, the pretreatment method includes adding an extracting solution to the sample to be tested, wherein the extracting solution is a mixture of methanol and acetonitrile, and the ratio of the mixed extracting solution is methanol: acetonitrile 3:1-1:2, wherein the addition of acetonitrile is beneficial to the removal of phospholipids in the plasma sample, improving the cleanliness of the solution after extraction, and reducing the matrix effect. The preferred ratio is methanol: acetonitrile 3:1, and the extraction recovery rate is the highest.
[0047] The sample to be tested is a blood sample of a subject, including whole blood, plasma or serum, and more preferably plasma.
[0048] The volume ratio of the sample to be tested to the extract is 1:1-5, preferably 1:3.
[0049] Furthermore, the detection method also includes preparing a standard curve using a calibrator and performing quality control using a quality control product.
[0050] The method for preparing the calibration working solution may include: using methanol to prepare each standard stock solution and a mixed stock solution, and then using a calibration diluent to prepare mixed standard working solutions of different concentrations.
[0051] Wherein, the calibration substance diluent is blank plasma.
[0052] The standard substance is a standard substance of tricyclic antidepressants; the tricyclic antidepressants are amitriptyline, nortriptyline, maprotiline, doxepin, nordoxepin, imipramine, desipramine, trimipramine, N-desmethyltrimipramine, clomipramine, N-desmethylclomipramine and doxepin.
[0053] Quality control was performed using quality control products at three concentration levels: low, medium, and high (i.e., the first quality control group, the second quality control group, and the third quality control group);
[0054] Specifically, the first quality control group: amitriptyline 48ng / mL, nortriptyline 48ng / mL, maprotiline 76.8ng / mL, doxepin 76.8ng / mL, nordoxepin 76.8ng / mL, imipramine 96ng / mL, desipramine 96ng / mL, trimipramine 96ng / mL, N-desmethyltrimipramine 51.2ng / mL, clomipramine 128ng / mL, N-desmethylclomipramine 128ng / mL, doxepin 64ng / mL;
[0055] The second quality control group: amitriptyline 120ng / mL, nortriptyline 120ng / mL, maprotiline 192ng / mL, doxepin 192ng / mL, nordoxepin 192ng / mL, imipramine 240ng / mL, desipramine 240ng / mL, trimipramine 240ng / mL, N-desmethyltrimipramine 128ng / mL, clomipramine 320ng / mL, N-desmethylclomipramine 320ng / mL, doxepin 160ng / mL;
[0056] The third quality control group: amitriptyline 240ng / mL, nortriptyline 240ng / mL, maprotiline 384ng / mL, doxepin 384ng / mL, nordoxepin 384ng / mL, imipramine 480ng / mL, desipramine 480ng / mL, trimipramine 480ng / mL, N-desmethyltrimipramine 256ng / mL, clomipramine 640ng / mL, N-desmethylclomipramine 640ng / mL, doxepin 320ng / mL.
[0057] Furthermore, an internal standard is added to the extract, so as to facilitate the subsequent quantification of the drug to be tested using an isotope internal standard method.
[0058] The isotope internal standards and their concentrations are: amitriptyline-D6 2340ng / mL, nortriptyline-D3 2340ng / mL, maprotiline-D3 3750ng / mL, doxepin-D3 3750ng / mL, nordoxepin-D3 3750ng / mL, imipramine-D3 4690ng / mL, desipramine-D3 4690ng / mL, N-desmethyltrimipramine-13C.D3 (wherein, trimipramine and N-desmethyltrimipramine use the same internal standard) 4690ng / mL, clomipramine-D3 6250ng / mL, N-desmethylclomipramine-D3 6250ng / mL, and doxepin-D6 5000ng / mL.
[0059] Furthermore, the sample pretreatment method includes: taking a sample to be tested, adding an extract (including an internal standard) thereto, and vortexing; taking the supernatant after centrifugation into a sample injection plate, adding water and mixing, which is the loading solution.
[0060] The specific method of LC-MS / MS for detecting the sample to be tested is:
[0061] Liquid chromatography conditions included:
[0062] Gradient elution was used, mobile phase A: aqueous solution containing 0.1-2 mmol / L ammonium acetate, 0.001-0.01% formic acid, and 5%-25% methanol; mobile phase B: pure methanol;
[0063] The mobile phase flow rate is 0.1-0.5 mL / min (preferably 0.3 mL / min); the column temperature is 30-45°C (preferably 40°C); the injection volume is 1-10 μL (preferably 5 μL);
[0064] The specific gradient elution method is: 0-2 min, 25% B-75% B, 2-3 min, 75% B-95% B, 3-4.5 min, 95% B, 4.5-4.6 min, 95% B-25% B, 4.6-6 min, 25% B.
[0065] Mass spectrometry conditions included:
[0066] Multiple ion reaction monitoring with positive electrospray ionization, ion source voltage (positive) 3500 V, carrier gas 40 Arb, auxiliary gas 10 Arb, ion transfer tube temperature 325°C, and spray chamber temperature 325°C.
[0067] The MRM mass spectrometry parameters are as follows:
[0068]
[0069] Furthermore, the mass spectrometry parameters of amitriptyline and maprotiline were optimized: amitriptyline: 278.19→218.125, 278.19→233.125, preferably 278.19→233.125 as the quantitative ion pair; maprotiline: 278.19→250.208, 278.19→219.25, preferably 278.19→219.25 as the quantitative ion pair, and the selected quantitative ion pairs had the least mutual interference.
[0070] In one or more specific embodiments of the present invention, a kit for specifically detecting multiple tricyclic antidepressants is provided, and the kit may include: a calibrator, a calibrator diluent, a quality control product, an internal standard, an extract, a sample injection plate and a chromatographic column.
[0071] The calibrator can be the above-mentioned lyophilized powder of the tricyclic antidepressant standard prepared by using the calibrator diluent. The concentration of each compound after the calibrator lyophilized powder is dissolved is:
[0072] Amitriptyline 600ng / mL, nortriptyline 600ng / mL, maprotiline 960ng / mL, doxepin 960ng / mL, nordoxepin 960ng / mL, imipramine 1200ng / mL, desipramine 1200ng / mL, trimipramine 1200ng / mL, N-desmethyltrimipramine 640ng / mL, clomipramine 1600ng / mL, N-desmethylclomipramine 640ng / mL, doxepin 800ng / mL.
[0073] The calibrator diluent may also be stored in the form of a lyophilized powder, the component of which is blank plasma.
[0074] The quality control product can also be the above-mentioned lyophilized powder of the standard tricyclic antidepressant prepared with the calibration diluent; more specifically, it has three concentration levels of low, medium and high quality control products, and the concentration of each compound after the quality control dry powder is dissolved is:
[0075] Quality Control I: Amitriptyline 48 ng / mL, Nortriptyline 48 ng / mL, Maprotiline 76.8 ng / mL, Doxepin 76.8 ng / mL, Nordoxepin 76.8 ng / mL, Imipramine 96 ng / mL, Desipramine 96 ng / mL, Trimipramine 96 ng / mL, N-Desmethyl Trimipramine 51.2 ng / mL, Clomipramine 128 ng / mL, N-Desmethyl Clomipramine 128 ng / mL, Doxepin 64 ng / mL
[0076] Quality Control II: Amitriptyline 120ng / mL, Nortriptyline 120ng / mL, Maprotiline 192ng / mL, Doxepin 192ng / mL, Nordoxepin 192ng / mL, Imipramine 240ng / mL, Desipramine 240ng / mL, Trimipramine 240ng / mL, N-Desmethyl Trimipramine 128ng / mL, Clomipramine 320ng / mL, N-Desmethyl Clomipramine 320ng / mL, Doxepin 160ng / mL
[0077] Quality Control III: Amitriptyline 240ng / mL, Nortriptyline 240ng / mL, Maprotiline 384ng / mL, Doxepin 384ng / mL, Nordoxepin 384ng / mL, Mipramine 480ng / mL, Desipramine 480ng / mL, Trimipramine 480ng / mL, N-Desmethyltrimpramine 256ng / mL, Clomipramine 640ng / mL, N-Desmethylclomipramine 640ng / mL, Doxepin 320ng / mL.
[0078] The internal standard can also be in the form of dry powder; the specific concentration of the internal standard dry powder after dissolution is:
[0079] Amitriptyline-D6 2340ng / mL, nortriptyline-D3 2340ng / mL, maprotiline-D3 3750ng / mL, doxepin-D3 3750ng / mL, nordoxepin-D3 3750ng / mL, imipramine-D3 4690ng / mL, desipramine-D3 4690ng / mL, N-desmethyltrimipramine-13C.D3 (trimipramine and N-desmethyltrimipramine use the same internal standard) 4690ng / mL, clomipramine-D3 6250ng / mL, N-desmethylclomipramine-D3 6250ng / mL, doxepin-D6 5000ng / mL.
[0080] The extract is a mixed extract of methanol and acetonitrile, with a volume ratio of 3:1-1:2;
[0081] The injection plate can be a 96-well injection plate.
[0082] The chromatographic column is from Shandong Yingsheng Biotechnology Co., Ltd., YS LCC 102MD, 2.1x100mm, 3μm.
[0083] In one or more specific embodiments of the present invention, the use of the above method and / or kit in any one or more of the following is provided:
[0084] a) Pharmacokinetic studies of tricyclic antidepressants;
[0085] b) Detection and evaluation of the efficacy of tricyclic antidepressants.
[0086] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.
[0087] Example 1: Instruments, Materials and Reagents
[0088] YS EXACT 9900MD ultra-high performance liquid chromatography tandem mass spectrometry detection system (Shandong Yingsheng Biotechnology Co., Ltd.), amitriptyline, nortriptyline, maprotiline, doxepin, nordoxepin, imipramine, desipramine, trimipramine, desmethyltrimipramine, clomipramine and N-desmethylclomipramine standards were purchased from Tianjin Alta Technology Co., Ltd., all compound isotope internal standard powders were products of Manhage (Shanghai) Biotechnology Co., Ltd., mass spectrometry grade methanol was purchased from MERK Company; blank plasma was purchased from Shanghai Pufen Biotechnology Co., Ltd.
[0089] Example 2: Preparation of calibrators, quality control products and internal standards and preparation of experimental solutions, comprising the following steps:
[0090] (1) Preparation of Calibrators
[0091] 1) Preparation of calibrator stock solution
[0092] Weigh the analyte amitriptyline, nortriptyline, maprotiline, doxepin, nordoxepin, imipramine, desipramine, trimipramine, desmethyltrimipramine, clomipramine and N-desmethylclomipramine standards respectively, add them into clean light-proof plastic reagent bottles, use methanol or acetonitrile to ultrasonically dissolve them, add appropriate amount of DMSO to promote the dissolution of substances that are difficult to dissolve, prepare high-concentration standard stock solutions, label them, and store them at -20°C or below for future use. Preparation: Dissolve the standard according to actual conditions. If the solid powder is of small quality, it can be dissolved directly in the bottle. Pay attention to the conversion of the mass of hydrochloride or other salts. The concentration of each analyte stock solution is: amitriptyline 9484.59μg / mL, nortriptyline 9090.81μg / mL, maprotiline 9502.25μg / mL, doxepin 9316.28μg / mL, nordoxepin 9283.8μg / mL, imipramine 8871.53μg / mL, desipramine 9176.49μg / mL, trimipramine 7443.81μg / mL, nortrimipramine (998.3μg / mL solution, no need to dissolve and prepare), clomipramine 9109.89μg / mL, N-desmethylclomipramine 4517.28μg / mL, doxepin 985μg / mL.
[0093] 2) Preparation of mixed stock solution of standard substances:
[0094] The stock solution in Table 1 is diluted to obtain a mixed standard solution. The dilution steps are shown in Table 1. After preparation, a label is attached and the solution is stored at -20°C or below for future use. See Table 1.
[0095] Table 1 Concentration and preparation method of each compound in mixed standard solution
[0096]
[0097] 3) Preparation of calibration solution
[0098] Add the mixed standard solution to the calibration diluent, and mix thoroughly. The concentration is shown in Table 2. After passing the quality inspection, dispense into 3 mL brown lyophilized bottles at a rate of 0.20 mL / bottle.
[0099] Table 2 Calibrator solution concentration
[0100]
[0101] 4) Freeze-drying of calibration products: Place the packaged calibration product solution in a freeze dryer for freeze drying. After the freeze-dried powder passes the quality inspection, cap and label it and store it at -18°C or below.
[0102] 5) Use of lyophilized powder of calibrator:
[0103] Take 0.2mL of pure water and dissolve it before use. The concentration after dissolution is the target concentration in Table 4. Dilute the highest point calibrator solution with calibrator diluent to 5 different concentrations of calibrator solutions, a total of 6 calibrator concentration points. The specific concentrations are as follows:
[0104] Amitriptyline 9.38ng / mL, 37.5ng / mL, 75ng / mL, 150ng / mL, 300ng / mL, 600ng / mL, Nortriptyline 9.38ng / mL, 37.5ng / mL, 75ng / mL, 150ng / mL, 300ng / mL, 600ng / mL, Maprotiline 15ng / mL, 60ng / mL, 120ng / mL, 240ng / mL, 480ng / mL, 960ng / mL, Doxepin 15ng / mL, 60ng / mL, 120ng / mL, 240ng / mL, 480ng / mL, 960ng / mL, nordoxepin 15ng / mL, 60ng / mL, 120ng / mL, 240ng / mL, 480ng / mL, 960ng / mL, imipramine 18.75ng / mL, 75ng / mL, 150ng / mL, 300ng / mL, 600ng / mL, 1200ng / mL, desipramine 18.75ng / mL, 75ng / mL, 150ng / mL, 300ng / mL, 600ng / mL, 1200ng / mL, Trimipramine 18.75ng / mL, 75ng / mL, 150ng / mL, 300ng / mL, 600ng / mL, 1200ng / mL, N-Demethyltrimipramine 10ng / mL, 40ng / mL, 80ng / mL, 160ng / mL, 320ng / mL, 640ng / mL , clomipramine 25ng / mL, 100ng / mL, 200ng / mL, 400ng / mL, 800ng / mL, 1600ng / mL, N-desmethylclomipramine 10ng / mL, 40ng / mL, 80ng / mL, 160ng / mL, 320ng / mL, 640ng / mL, doxepin 12.5ng / mL, 50ng / mL, 100ng / mL, 200ng / mL, 400ng / mL, 800ng / mL.
[0105] (2) Preparation of quality control products
[0106] 1) Quality Control I: Refer to step 3) of (1) in Example 2, dilute the sample with the calibrator diluent (not freeze-dried) 12.5 times and inspect the sample. If the sample is qualified, dispense the sample into 3 mL brown freeze-dried bottles at a rate of 0.2 mL / bottle and place the bottle in a freeze dryer. After freeze-drying, inspect the sample. If the sample is qualified, cap and label the bottle and store it at -18°C or below.
[0107] 2) Quality Control II: Refer to step 3) in (1) of Example 2, dilute the sample 5 times with the calibrator diluent (not freeze-dried) and perform quality inspection. If the sample is qualified, dispense the sample into 3 mL brown freeze-dried bottles at a rate of 0.2 mL / bottle and place the bottle in a freeze dryer. Perform quality inspection after freeze drying. If the sample is qualified, cap and label the bottle and store it at -18°C or below.
[0108] 3) Quality Control III: Refer to step 3) in (1) of Example 2, dilute the sample with the calibrator diluent (not freeze-dried) 2.5 times and perform quality control. If the sample is qualified, dispense it into 3 mL brown freeze-dried bottles at a rate of 0.2 mL / bottle and place it in a freeze dryer. After freeze-drying, perform quality control. If the sample is qualified, cap and label it and store it at -18°C or below.
[0109] 4) Use of freeze-dried powder of quality control product: Add 200 μL of pure water to each vial of dry powder of quality control I and quality control II, and dissolve and mix well.
[0110] (3) Preparation of internal standard
[0111] 1) Preparation of internal standard stock solution: Weigh the dry powder of internal standard of the above compounds respectively, add them into clean light-proof plastic reagent bottles, dissolve them by ultrasonication with methanol, add appropriate amount of DMSO to promote the dissolution of substances that are not easily soluble, prepare high-concentration internal standard stock solution, mark it, and store it at -20℃ or below for future use. Prepare the dissolved standard according to the actual situation. If the solid powder is of small specification and mass, it can be dissolved directly in the bottle. Pay attention to the mass conversion of hydrochloride or other salts. The stock solution concentrations of each internal standard are as follows: amitriptyline-D6 2.18 mg / mL, nortriptyline-D3 2.13 mg / mL, maprotiline-D3 2.09 mg / mL, doxepin-D3 2.17 mg / mL, nordoxepin-D3 2.10 mg / mL, imipramine-D3 2.03 mg / mL, desipramine-D3 2.03 mg / mL, N-desmethyltrimipramine-13C.D3 (trimipramine and N-desmethyltrimpramine use the same internal standard) 1.05 mg / mL, clomipramine-D3 2.0 mg / mL, N-desmethylclomipramine-D3 2.02 mg / mL, doxepin-D6 5 mg / mL.
[0112] 2) Preparation of internal standard mixed solution: Take out the internal standard stock solution from the -18℃ refrigerator, arrange it in order in the kit, use methanol to prepare the internal standard mixed solution concentration according to the formula requirements, mix it evenly and then conduct quality inspection. If it is qualified, it will be packaged into 0.5mL brown cryotubes at 100μL / bottle. Internal standard concentrations: amitriptyline-D6 2340ng / mL, nortriptyline-D3 2340ng / mL, maprotiline-D3 3750ng / mL, doxepin-D3 3750ng / mL, nordoxepin-D3 3750ng / mL, imipramine-D3 4690ng / mL, desipramine-D3 4690ng / mL, N-desmethyltrimipramine-13C.D3 (trimipramine and N-desmethyltrimipramine use the same internal standard) 4690ng / mL, clomipramine-D3 6250ng / mL, N-desmethylclomipramine-D3 6250ng / mL, doxepin-D6 5000ng / mL
[0113] 3) Internal standard dry powder: Blow nitrogen through the internal standard mixed solution after packaging for 15 minutes, observe the materials in the reagent bottle until there is no liquid in the bottle, tighten the bottle cap and send it for inspection. After passing the inspection, label it and store it at -18℃ or below.
[0114] 4) Use of internal standard dry powder: Before opening the lid, centrifuge the internal standard dry powder at 12000rpm for 1min, add 100μL methanol, ultrasonicate for 2min, vortex for 1min, and centrifuge for 30s. Calculate the amount of internal standard working solution based on the number of samples to be tested, dilute the internal standard concentrate with the extract at a ratio of 1:149, and mix the liquid thoroughly.
[0115] Example 3: Human plasma sample pretreatment process, comprising the following steps:
[0116] Take 50 μL of sample in a 1.5 mL centrifuge tube, add 150 μL of extract (including mixed internal standard working solution), vortex at 2500 rpm for 5 min; centrifuge at 12000 rpm for 5 min; take 100 μL of supernatant into a 96-well sample plate, add 100 μL of pure water and mix well, and the sample to be tested is processed.
[0117] Example 4: Liquid chromatography-tandem mass spectrometry detection
[0118] (1) Place the 96-well sample plate into the autosampler, enable the application software, and create a sample list. The sample to be tested enters the chromatographic column (YS LCC 102MD, 2.1x100mm, 3μm, Shandong Yingsheng Biotechnology Co., Ltd.) through gradient elution mode for separation, with an injection volume of 5μL, a column temperature of 40°C, and chromatographic gradient elution conditions: 0-2min, 25% B-75% B, 2-3min, 75% B-95% B, 3-4.5min, 95% B, 4.5-4.6min, 95% B-25% B, 4.6-6min, 25% B, where mobile phase A: aqueous solution containing 1mmoL / L ammonium acetate, 0.005% formic acid, and 25% methanol; mobile phase B: pure methanol.
[0119] (2) Mass spectrometry conditions: ion source voltage (positive) 3500 V, carrier gas 40 Arb, auxiliary gas 10 Arb, ion transfer tube temperature 325° C., nebulizer temperature 325° C., multiple ion reaction monitoring (MRM) mode using positive ion electrospray ionization, the conditions are as follows Table 3:
[0120] Table 3 MRM mode parameters
[0121]
[0122]
[0123] (3) Data processing
[0124] Open the appropriate software for the instrument (YS EXACT 9900MD: TraceFinder), select the corresponding data for result analysis. First, use the concentration of the calibrator as the horizontal axis and the ratio of the peak area of the calibrator to the internal standard as the vertical axis to draw a standard curve, obtain the linear equation y=bx+a, substitute the peak area ratio of the sample to the internal standard into the equation, and calculate the concentration of the analyte in the sample.
[0125] Example 5: Calculation of ion channel interference rates of amitriptyline and maprotiline isomers
[0126] (1) By optimizing the mass spectrometry parameters, amitriptyline has the following six ion pairs: 278.19→91.05, 278.19→105.05, 278.19→117.05.05, 278.19→194.13, 278.19→218.13, 278.19→233.13; maprotiline has the following six ion pairs: 278.19→117.13, 278.19→169.17, 278.19→178.13, 278.19→191.08, 278.19→219.25, 278.19→250.21.
[0127] (2) Amitriptyline and maprotiline have the same ion pairs: 278.19→117.13, 278.19→191.08
[0128] (3) Interference channel of maprotiline in amitriptyline: 278.19→178.13 (strong), 278.19→169.17 (weak), 278.19→219.25 (weak), 278.19→250.21 (weak)
[0129] (4) Interference channel containing amitriptyline in maprotiline: 278.19→91.05 (strong), 278.19→105.05 (strong)
[0130] (5) From (1) to (4), it can be seen that the ion pairs between the two compounds have different degrees of interference. The ion channels with weaker interference are selected as the quantitative ion pairs and qualitative ion pairs for the detection of amitriptyline and maprotiline to calculate the interference rate between the compounds. After calculation, the interference rates of the quantitative ion pairs all meet the technical requirements, as shown in Table 4 below:
[0131] Table 4 Calculation results of channel interference rate of amitriptyline and maprotiline
[0132]
[0133] Example 6: Method Validation
[0134] (1) Specificity: In the MRM detection chromatograms of the 12 TCAs antidepressant drugs such as amitriptyline using liquid chromatography-tandem mass spectrometry, the peak shapes of each compound in the plasma sample were symmetrical, with little interference from impurity peaks.
[0135] (2) Linear range: The isotope internal standard method was used to establish the quantitative curve of the calibrator. The concentrations of 12 TCAs such as amitriptyline in human plasma were tested. The linear range and correlation coefficient r of each compound were as follows: amitriptyline 9.38-600 ng / mL-0.9993, nortriptyline 9.38-600 ng / mL-0.9997, maprotiline 15-960 ng / mL-0.9996, doxepin 15-960 ng / mL-0.9996, nordoxepin 15-960 ng / mL-0.9996, imipramine 18.75-1200 ng / mL-0.9997, desipramine 18.75-1200 ng / mL-0.9996, trimipramine 18.75-1200 ng / mL The linearity of each compound can cover the clinical reference range.
[0136] (3) Limit of quantitation: Take a blank sample and add the standard solution to the prepared quantitative limit concentration of the evaluated method. Process 5 samples in parallel and repeat the measurement 3 times for each sample to obtain the quantitative limit of each compound. The cvs are all within 15%: amitriptyline 9.38 ng / mL, nortriptyline 9.38 ng / mL, maprotiline 15 ng / mL, doxepin 15 ng / mL, nordoxepin 15 ng / mL, imipramine 18.75 ng / mL, desipramine 18.75 ng / mL, trimipramine 18.75 ng / mL, N-desmethyltrimipramine 10 ng / mL, clomipramine 25 ng / mL, N-desmethylclomipramine 10 ng / mL, doxepin 12.5 ng / mL.
[0137] (4) Precision and recovery: Take 50 μL of human plasma and add mixed standard stock solutions at three concentration levels: low, medium and high. Each concentration level is processed in parallel for 5 times. The sample concentration is determined using the calibration curve, and the recovery is calculated. This experiment measured three analytical batches and completed the test within 2-3 days to evaluate the precision. The results showed that the indicators of each compound met the requirements: the recovery rate met the requirements of 85%-115%; the coefficient of variation of intra-batch precision and inter-batch precision CV≤15%. The results are as follows: the recovery rate of amitriptyline spiked is 100.46%-101.98%, the intra-batch precision is 2.60%-3.03%, and the inter-batch precision is 2.8%; nortriptyline is 99.37%-104.58%, the intra-batch precision is 2.16%-3.77%, and the inter-batch precision is 3.34%; maprotiline is 101.73%-102.92%, the intra-batch precision is 1.18%-2.72%, and the inter-batch precision is 2.07%, doxepin 99.66%-100.71%, intra-batch precision 1.76%-2.75%, inter-batch precision 2.32%, nordoxepin 98.94%-101.67%, intra-batch precision 2.22%-2.63%, inter-batch precision 2.28%, imipramine 100.21%-101.70%, intra-batch precision 1.39%-2.83%, inter-batch precision 2.36%, Desipramine 101.00%-102.95%, intra-batch precision 2.03%-2.64%, inter-batch precision 2.16%, trimipramine 102.37%-104.29%, intra-batch precision 1.93%-2.13%, inter-batch precision 2.0%, N-desmethyltrimipramine 99.57%-103.33%, intra-batch precision 2.19%-2.51%, inter-batch precision 2.28%, Clomipramine 101.99%-103.55%, intra-batch precision 1.32%-2.41%, inter-batch precision 2.22%; N-desmethylclomipramine 102.18%-104.37%, intra-batch precision 2.12%-3.49%, inter-batch precision 3.38%; doxepin 100.64%-101.60%, intra-batch precision 1.81%-2.66%, inter-batch precision 2.32%.
[0138] (5) A blank sample was injected immediately after the ULOQ sample to investigate the carryover effect. None of the 12 compounds showed any carryover, which met the technical requirements.
[0139] (6) Extraction recovery rate: Under the extraction with methanol:acetonitrile (3:1), the extraction recovery rate of each compound is shown in Table 5. The extraction recovery rate of each compound is within 95%-121%.
[0140] Table 5 Extraction recovery of each compound component
[0141]
[0142] Example 7: A liquid chromatography tandem mass spectrometry kit for specific determination of 12 tricyclic antidepressants such as amitriptyline in human plasma, the components of the kit are shown in Table 6:
[0143] Table 6 Composition of a liquid chromatography tandem mass spectrometry kit for specific determination of amitriptyline and other 12 tricyclic antidepressants in human plasma
[0144]
[0145]
[0146] It should be noted that the above examples are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention is described in detail with reference to the given examples, those skilled in the art may modify or replace the technical solution of the present invention as needed without departing from the spirit and scope of the technical solution of the present invention.
Claims
1. A method for specifically detecting multiple tricyclic antidepressants, characterized in that: The tricyclic antidepressants include amitriptyline, nortriptyline, maprotiline, doxepin, N-nordoxepin, imipramine, desipramine, trimipramine, N-nortrimipramine, clomipramine, N-norclomipramine and doxepin. The method includes: detecting the pre-treated sample based on LC-MS / MS; The pretreatment includes adding an extract to the sample to be tested, wherein the extract is a mixture of methanol and acetonitrile, and the ratio of the mixed extract is methanol:acetonitrile 3:1-1:2; The sample to be tested is a blood sample of a subject, including whole blood, plasma or serum; The volume ratio of the sample to be tested to the extract is 1:1-5; The specific method of LC-MS / MS for detecting the sample to be tested is: Liquid chromatography conditions included: The chromatographic column is YS LCC 102MD, 2.1x100mm, 3μm; Gradient elution was used, mobile phase A: aqueous solution containing 0.1-2 mmol / L ammonium acetate, 0.001-0.01% formic acid, and 5%-25% methanol; mobile phase B: pure methanol; The flow rate of the mobile phase is 0.1-0.5 mL / min; the column temperature is 30-45°C; the injection volume is 1-10 μL; The gradient elution mode is as follows: 0-2 min, 25% B-75% B, 2-3 min, 75% B-95% B, 3-4.5 min, 95% B, 4.5-4.6 min, 95% B-25% B, 4.6-6 min, 25% B; Mass spectrometry conditions included: Multiple ion reaction monitoring with positive electrospray ionization, ion source voltage 3500 V, carrier gas 40 Arb, auxiliary gas 10 Arb, ion transfer tube temperature 325 °C, spray chamber temperature 325 °C; The MRM mass spectrometry parameters are as follows: Amitriptyline: 278.19 / 233.125 as quantitative ion pair; Maprotiline: 278.19 / 219.25 as quantitative ion pair; An internal standard is also added to the extract; The isotopic internal standards and their concentrations were: amitriptyline-D6 2340ng / mL, nortriptyline-D3 2340ng / mL, maprotiline-D3 3750ng / mL, doxepin-D3 3750ng / mL, N-nordoxepin-D3 3750ng / mL, imipramine-D3 4690ng / mL, desipramine-D3 4690ng / mL, N-desmethyltrimpramine-13C,D3 4690ng / mL, clomipramine-D3 6250ng / mL, N-desmethylclomipramine-D3 6250ng / mL, and doxepin-D6 5000ng / mL.
2. The method according to claim 1, characterized in that The detection method also includes preparing a standard curve with a calibrator and performing quality control with a quality control product; The method for preparing the calibration working solution includes: using methanol to prepare each standard stock solution and a mixed stock solution, and then using the calibration diluent to prepare mixed standard working solutions of different concentrations; Wherein, the calibration substance diluent is blank plasma; The standard substance is a standard substance of tricyclic antidepressants; the tricyclic antidepressants are amitriptyline, nortriptyline, maprotiline, doxepin, N-nordoxepin, imipramine, desipramine, trimipramine, N-nortrimipramine, clomipramine, N-norclomipramine and doxepin; Quality control was performed using quality control products at three concentration levels: low, medium, and high; The first quality control group: amitriptyline 48ng / mL, nortriptyline 48ng / mL, maprotiline 76.8ng / mL, doxepin 76.8ng / mL, N-nordoxepin 76.8ng / mL, imipramine 96ng / mL, desipramine 96ng / mL, trimipramine 96ng / mL, N-norttripramine 51.2ng / mL, clomipramine 128ng / mL, N-norclomipramine 128ng / mL, doxepin 64ng / mL; The second quality control group: amitriptyline 120ng / mL, nortriptyline 120ng / mL, maprotiline 192ng / mL, doxepin 192ng / mL, N-nordoxepin 192ng / mL, imipramine 240ng / mL, desipramine 240ng / mL, trimipramine 240ng / mL, N-nortripramine 128ng / mL, clomipramine 320ng / mL, N-norclomipramine 320ng / mL, doxepin 160ng / mL; The third quality control group: amitriptyline 240ng / mL, nortriptyline 240ng / mL, maprotiline 384ng / mL, doxepin 384ng / mL, N-nordoxepin 384ng / mL, imipramine 480ng / mL, desipramine 480ng / mL, trimipramine 480ng / mL, N-nortripramine 256ng / mL, clomipramine 640ng / mL, N-norclomipramine 640ng / mL, doxepin 320ng / mL.
3. The method according to any one of claims 1 to 2, characterized in that: The sample pretreatment includes: taking the sample to be tested, adding the extract containing the internal standard thereto, and vortexing; after centrifugation, taking the supernatant into the sample injection plate, adding water and mixing, which is the loading solution.
4. Application of the method according to any one of claims 1 to 3 in any one or more of the following: a) Pharmacokinetic studies of tricyclic antidepressants; b) Detection and evaluation of the efficacy of tricyclic antidepressants.
Citation Information
Patent Citations
Determination of antidepressants by mass spectrometry
CN114127554A
Kit for simultaneously and quantitatively detecting 78 neuropsychiatric drugs
CN114935620A
JP平9316.28
